Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) related to its sale to Vertex Pharmaceuticals Incorporated. Under the terms of the proposed transaction, Crinetics shareholders are expected to receive $85.00 per share in cash.
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) related to its sale to Vertex Pharmaceuticals Incorporated. Under the terms of the proposed transaction, Crinetics shareholders are expected to receive $85.00 per share in cash.